Arab Finance: Net profits after tax of Kahira Pharmaceuticals and Chemical Industries Company increased by 24.5% to EGP 552.540 million in fiscal year (FY) 2025/2026 from EGP 443.721 million in FY2024/2025, according to the financial results.
Sales jumped by 21% year-on-year (YoY) to EGP 2.510 billion at the end of June 2026, up from EGP 2.074 billion.
Basic earnings per share (EPS) amounted to EGP 37.0 in FY2025/2026, an annual rise from EGP 29.7.
At the end of March 2026, the net profits of Kahira Pharmaceuticals hiked by 17.26% YoY to EGP 412.811 million, compared to EGP 352.038 million.